Patrick Nef, PhD co-founder and CEO. PProf. Patrick Nef holds a PhD from the University of Geneva (Switzerland) and has over 30 years of experience in R&D and early drug development in academia, biotechnology industry, small and large pharmaceuticals and non-for-profit public-private partnership foundation. He co-founded TransCure bioServices SAS in 2012 to develop human immune system mouse models for immuno-oncology, infectious and inflammation diseases. Previously he served as Chief Business Officer at Medicines for Malaria Venture from 2008 to 2011 to assist their efforts to reduce the burden of malaria in endemic countries by discovering, developing and facilitating delivery of new, effective and affordable antimalarial drugs. He was Chief Scientific Officer at Synosia Therapeutics Inc. from 2006 to 2008 to develop drugs for neuro-degenerative and psychiatric disorders, Chief Executive Officer at Faust Pharmaceutical SA in 2005 to develop CNS drugs and as Global Business Director, Vice-President & Disease Area Head for CNS at F. Hoffmann-La Roche Ltd. from 1996-2005. Before that he was Assistant Professor in the Biochemistry Department at the University of Geneva, Switzerland from 1992 and has published more than 46 peer-reviewed articles/reviews/patents.
Sebastien Tabruyn, PhD Chief Scientific Officer (CSO). Sebastien Tabruyn holds a PhD in Molecular Biology from the University of Liege (Belgium). After 15 years of experience as Project leader in renowned international academic research institutes including UCSF (California, USA), the Centre for Cancer Biology (Adelaide, Australia) and the University of Maastricht (Netherlands), he joined TransCure bioServices in 2013 as Head of Molecular Biology and Oncology. Sebastien Tabruyn published 35 peer-reviewed publications in the field of Oncology, Angiogenesis, Inflammation and Immunity.
Kiave-Yune HoWangYin, PhD Director of Innovation. Kiave HoWangYin holds a PhD in Immunology / Oncology from the Paris 7 University (France). She worked for 5 years in the Center of Cardiovascular Research (Paris) as scientist in the field of inflammation and angiogenesis. She published more than 10 papers in peer-reviewed international journals in oncology and inflammation.
Catherine Verhaeghe, PhD Director of Operations. Catherine Verhaeghe holds a PhD in Molecular Biology from the University of Liege (Belgium). She joined David Erle Lab at UCSF (USA) where she identified new molecules involved in goblet cell hyperplasia in lung and intestinal diseases. She has expertise in Project/Team Management, In vivo mouse models, Inflammation, Signalling Pathway and Oncology. She published more than 10 papers in peer-reviewed international journals in the field of Cystic fibrosis, airway and intestinal inflammation, oncology.
Antoine Poskin, DVM, PhD Veterinary Chief Officer and Animal Facility Manager. Antoine started his career as a veterinarian, then worked as scientific researcher for Iprabio (Mons, Belgium), the Blood Brain Barrier Laboratory (LBHE, Lens, France) and Sciensano (formerly Veterinary and Agrochemical Research Centre, Brussels, Belgium). Antoine published 11 peer-reviewed articles and obtained a PhD in Veterinary Science from the University of Liege (Belgium). After his PhD, he first joined the respiratory franchise of Novartis as Medical Sciences Liaison, then moved to TransCure bioServices as Veterinary Chief Officer and Animal Facility Manager. At TransCure bioServices, he is in charge of the animal facility and makes sure that corporate policy meets the highest quality and ethical standards for our clients dedicating his time to the up and coming AAALAC accreditation.
Project Leaders Team
Florent Arbogast, PhD, started studying immunology and antiviral responses during his Master degree at the University of Strasbourg, France. He pursued a thesis on autophagy and its function in various immune compartments, in particular in antigen presenting cells and T cells. For his post-doctoral training, Florent joined the Yale University, USA where he worked on different models of humanized mice and human immunity.
Laïla Letaïef holds a PhD in Immunology from the University Paris VI, France. During the past years, she worked on the interactions between immune cells and the peripheral nervous system in human and mice lung tumors. She joined the TransCure bioServices Team as a project leader.
Touyana Semenova, MD, PhD, Project Leader holds MD from the Irkutsk State Medical University (Russia) and PhD in Virology from the University Grenoble Alpes (France). She has completed her postgraduate training in Medical Biology at Grenoble Alpes University Hospital. Then Touyana joined the Department of Infectious Diseases and Immunology at the University of Florida (USA) where she studied neutralizing antibodies against Zika and Dengue virus infections applying single-cell technology. She published 14 papers in peer-reviewed journals in the field of Infectious Diseases, Virology, and Immunology including 3 book chapters.
Ha-Yeon KIM-PENARD holds a PhD in Cell and Molecular Biology from the University of Paris (France). She worked in Curie Institute (Orsay, France) in the field of cancer biology in melanoma.
Iris Nkamba holds a PhD in immunology from Paris Descartes University. She started her curriculum with a life science engineering diploma from AgroParisTech, then specialized on mucosal immunology for a year of internships in the US and Australia. During her master’s and PhD in Nadine Cerf-Bensussan’s lab at the Imagine Institute in Paris, she pursued her focus on intestinal immunology and host-microbiota interactions. Iris now works as a Project Leader at TransCure bioServices.
Pierre Wallet did his PhD in immunology/infectiology at the University Claude Bernard Lyon 1 and at the International Center for Research in Infectious Diseases (CIRI). He studied inflammasome activation by immune cells after the detection of intracellular pathogens. He followed by exploring cancer/immune cells interactions with a scientist position at the Cancer Treatment and Research Center “City of Hope” in Los Angeles. HE studied the interaction of the immune and cancer cells, analyzed a clinical trial and profiled, using “single cell RNA seq”, postmortem patients with breast cancers. His work has led to the publication of several papers in peer-reviewed international journal.
Hélène DELPECH holds a Master’s degree in Biotechnology from the University of Montpellier (France). She then joined the Molecular Genetics Institute of Montpellier as a research engineer, and worked 5 years in the fields of angiogenesis and metabolism. There, Hélène acquired strong skills in histology and in molecular and cellular biology. She then joined the Cancerology Institute of Montpellier as animal experimentation engineer where she also stayed five years. At the institute, Hélène was in charge of establishing a PDX model library, and handled all subsequent in vivo pharmacology experiments. At TransCure she is managing the PDX studies in the context of TCS’ collaboration with Champions Oncology.
Customers Support Team
Hendrick CLAEYS, Global Sales Director, is in charge of implementing and supporting the sales activities, identify new market opportunities, and define the actions required to bring a new dynamic to the business. His vision and experience within the life-science field helps positioning TransCure bioServices further in being the leader in the humanized mice market.
Oriane FERRERA, Business Development Manager, is holding a master’s degree in Sciences of Marketing from the Dublin business school with a specialization in PR and event. Dedicated to our customers, she is the main point of contact to assist you in the elaboration of your preclinical studies at TransCure.
TransCure bioServices SAS is accredited by the french Ministère de l’Enseignement Supérieur et de la Recherche MESR and the Haut Conseil des Biotechnologies to perform in vivo pharmacology studies for worldwide international customers.
As a preferred provider CRO for our customer’s in vivo pharmacology studies, our team members emphasise competence, transparency, and enthusiasm. We are very pro-active, SOP driven to deliver the best, high quality results you are looking for. Our recognised alliance management skills is appreciated by our clients.
Regarding animal welfare, we apply the strictest regulation in compliance with the national laws of France, guidelines and regulations to underpin our own global bioethical chart:
1 – We are committed to the 3Rs which are, Replacement, Reduction and Refinement, to good science and to the responsible use of animals, which are treated with the highest standards of care and ethics. We only work with highly qualified staffs which are trained regularly in order to ensure the best treatment for research animals. We have started in 2018 the AAALAC accreditation/validation process, and have successfully been audited by large pharma companies since the company creation.
2 – In addition to the inspections by government authorities, we have a formal program of regular peer reviews of our internal animal and laboratory research facilities, conducted by the biopark’s ethical committee and an independent veterinarian.